%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2014-11-24T11:42:58-05:00
2014-11-24T11:42:59-05:00
2014-11-24T11:42:59-05:00
Adobe InDesign CC 2014 (Windows)
uuid:2a635b60-d5a0-46a3-9f73-c6516e3876ca
xmp.did:C27AEA4A6D05DF119214F7D7B600E79B
xmp.id:4d02ca43-13f6-f542-93f5-d3e91137458f
proof:pdf
xmp.iid:ee0c5901-0218-8d48-b0ba-79b7de1c391d
xmp.did:7e94c94b-c4e3-064d-961c-fbd16089be29
xmp.did:C27AEA4A6D05DF119214F7D7B600E79B
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2014 (Windows)
/
2014-11-24T11:42:58-05:00
application/pdf
Adobe PDF Library 11.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
38 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
10 0 0 10 37.132 27.748 Tm
(2)Tj
/Span<>> BDC
( )Tj
EMC
/T1_1 1 Tf
30.511 0 Td
(PHARMACOLOGY WATCH)Tj
/T1_0 1 Tf
5.83 0 0 5.83 476.6669 31.078 Tm
(\256)Tj
10 0 0 10 481.3309 27.748 Tm
( / )Tj
(December)Tj
( 2014)Tj
11 0 0 11 37.132 748 Tm
(nearly 10.000 who had received a drug-eluting )Tj
0 -1.182 TD
(stent and 12 months of aspirin and a thienopyri)Tj
(-)Tj
T*
(dine were randomized to an additional 18 months )Tj
0 -1.182 TD
(dual platelet therapy vs aspirin plus placebo. )Tj
0 -1.182 TD
(Aspirin plus a thienopyridine reduced the rate of )Tj
T*
(stent thrombosis compared to placebo \(0.4% vs )Tj
T*
(1.4% HR 0.29 [95% CI, 0.17-0.48]; P<0.001\). )Tj
T*
(Major adverse cardiovascular and cerebrovascular )Tj
T*
(events were also significantly reduced \(HR 0.71, )Tj
0 -1.182 TD
(P>0.001\) as was the rate of myocardial infarc)Tj
(-)Tj
0 -1.182 TD
(tion \(HR 0.47, P<0.001\). The all cause death rate )Tj
T*
(was slightly higher in the dual therapy group \(HR )Tj
T*
(1.32, P=0.05\) and there was more major bleeding )Tj
T*
(with dual therapy \(2.5% vs 1.6%, P=0.001\). The )Tj
0 -1.182 TD
(authors conclude that dual antiplatelet therapy )Tj
0 -1.182 TD
(beyond 1 year after a drug-eluting stent, compared )Tj
T*
(to aspirin alone, is associated with lower rates of )Tj
T*
(stent thrombosis and major adverse cardiovascular )Tj
T*
(and cerebrovascular events but with a high rate )Tj
T*
(of bleeding \(NEJM published online November )Tj
0 -1.182 TD
(16, 2014, DOI:10.1056/NEJMoa1409312\). The )Tj
0 -1.182 TD
(increase in all-cause mortality is being further )Tj
T*
(studied. )Tj
1.093 -1.182 Td
(Nonsteroidal anti-inflammatory drugs )Tj
-1.093 -1.182 Td
(\(NSAIDs\) increase the risk of bleeding in patients )Tj
0 -1.182 TD
(with atrial fibrillation \(AF\) according to a new )Tj
0 -1.182 TD
(study. In a study of over 150,000 patients with )Tj
T*
(AF, nearly 54,000 were prescribed a NSAID dur)Tj
(-)Tj
T*
(ing the 6.2 years of the study. The risk of serious )Tj
T*
(bleeding within 3 months of taking a two week )Tj
T*
(course of an NSAID was 3.5/1000 compared with )Tj
0 -1.182 TD
(1.5/1000 for patients not on a NSAID. The risk )Tj
0 -1.182 TD
(was even higher if AF patients were on an oral )Tj
T*
(anticoagulant. NSAIDs were associated with an )Tj
T*
(increased risk of bleeding and thromboembolism )Tj
T*
(regardless of antithrombotic regimens or NSAID )Tj
0 -1.182 TD
(type. Higher doses of NSAIDs increased the risk of )Tj
0 -1.182 TD
(bleeding and naproxen and diclofenac were asso)Tj
(-)Tj
T*
(ciated with the highest risk. The authors recom)Tj
(-)Tj
T*
(mend that \223NSAIDs should be discouraged unless )Tj
T*
(other possibilities\205 have been exhausted\224 in AF )Tj
T*
(patients and physicians should \223exercise caution )Tj
0 -1.182 TD
(with NSAIDs in patients with AF.\224 \(Ann Int Med )Tj
0 -1.182 TD
(2014;161:690-698\). Although some NSAIDs con)Tj
(-)Tj
T*
(ferred a higher risk, even the COX-2 inhibitors )Tj
T*
(celecoxib and the now banned rofecoxib increased )Tj
T*
(bleeding risk. )Tj
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
<0051>Tj
0 0 0 1 k
/GS0 gs
/T1_2 1 Tf
13 0 0 13 37.132 123 Tm
(FDA Actions)Tj
/T1_0 1 Tf
11 0 0 11 49.156 111 Tm
(The FDA has approved a new single entity )Tj
-1.093 -1.182 Td
(hydrocodone product with abuse deterrent proper)Tj
(-)Tj
T*
(ties. The new hydrocodone product is indicated )Tj
25.261 60.273 Td
(for pain severe enough to require daily, around-)Tj
T*
(the-clock, long-term opioid therapy. The drug is )Tj
T*
(not approved for short term or as-needed pain )Tj
0 -1.182 TD
(relief. The tablet is difficult to crush or dissolve )Tj
0 -1.182 TD
(and forms a thick hydrogel when tampered with )Tj
T*
(that is difficult to inject. Hydrocodone extended )Tj
T*
(release is manufactured by Purdue Pharma and is )Tj
T*
(marketed as Hysingla ER. It is offered in 20, 30, )Tj
0 -1.182 TD
(40, 60, 80, 100, and 120 mg strengths. This prod)Tj
(-)Tj
0 -1.182 TD
(uct offers an alternative to Zogenix\222s Zohydro, )Tj
T*
(also a single agent hydrocodone product, which )Tj
T*
(was approved by the FDA last year and was )Tj
T*
(roundly criticized because of lack of tamper-proof )Tj
T*
(qualities. The maximum dose of Zohydro is 50 )Tj
0 -1.182 TD
(mg. Zogenix is working on their own tamper-)Tj
0 -1.182 TD
(proof tablet which may be marketed as within the )Tj
T*
(next 6 months.)Tj
1.093 -1.182 Td
(The FDA has \223concerns\224 whether two generic )Tj
-1.093 -1.182 Td
(versions of extended-release methylphenidate )Tj
0 -1.182 TD
(\(Concerta\) are therapeutically equivalent to the )Tj
0 -1.182 TD
(brand-name drug. Methylphenidate is used to treat )Tj
T*
(attention-deficit hyperactivity disorder in adults )Tj
T*
(and children. The two approved generics manu)Tj
(-)Tj
T*
(factured by Mallinckrodt and Kudco Ireland Ltd )Tj
-0.002 Tw T*
[(\223may deliver the drug in )0.5(the body at a slower )0.5(rated )]TJ
0 Tw 0 -1.182 TD
(during the 7-12 hour range\224 according to the FDA )Tj
0 -1.182 TD
(statement. Janssen, the manufacturer of brand )Tj
T*
(name Concerta also makes an authorized generic )Tj
-0.003 Tw T*
(marketed by Actavis that is identical to the original )Tj
0 Tw T*
(product and has been found to be bioequivalent. )Tj
0 -1.182 TD
(The two generics of concern will stay on the mar)Tj
(-)Tj
0 -1.182 TD
(ket and patients should stay on the drugs unless )Tj
T*
(the drug is not providing the desired effect. )Tj
1.093 -1.182 Td
(The FDA\222s Endocrinologic and Metabolic Drug )Tj
-1.093 -1.182 Td
(Advisory Committee has reviewed liraglutide for )Tj
T*
(the new indication of weight management and )Tj
0 -1.182 TD
(found it to be safe and effective enough to warrant )Tj
0 -1.182 TD
(approval. Liraglutide, a GLP-1-receptor agonist, )Tj
T*
(is currently marketed by Novo Nordisk as Victoza )Tj
T*
(for the treatment of type 2 diabetes. Studies )Tj
T*
(presented to the committee showed that obese )Tj
0 -1.182 TD
(patients who injected 3 mg of liraglutide daily )Tj
0 -1.182 TD
(lost at least 5% of body weight, including 22% )Tj
T*
(of participants who lost 10%. There was concern )Tj
T*
(voiced by one reviewer regarding an imbalance in )Tj
T*
(the number of breast cancers in women taking the )Tj
T*
(drug and there has also been lingering concerns )Tj
0 -1.182 TD
(about thyroid cancers, but the committee felt that )Tj
0 -1.182 TD
(these issues could be studied in post-marketing )Tj
T*
(studies. If approved by the FDA for weight loss, )Tj
T*
(liraglutide will be marketed for that indication as )Tj
T*
(Saxenda. )Tj
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
<0051>Tj
ET
endstream
endobj
39 0 obj
<>
endobj
11 0 obj
<>
endobj
12 0 obj
<>
endobj
40 0 obj
<>
endobj
47 0 obj
<>
endobj
48 0 obj
<>stream
HdN#G=ObusK\`f2̂OJ>nw7hSާN/}z|:N˷~,_Wf;grus3]~~1/_OWuriߧt{;~~xy>ί?|>c?>^i>7`/a_v۫xf/Nڟ9!ol<4<2:6#ofofofofollFyK*[Uvd^9r$Gy